Mammary carcinomas are aggressive neoplasms and a significant cause of mortality in female cats. Despite surgical removal, feline mammary carcinoma (FMC) often recurs or metastasizes. Specific tumour biomarkers are necessary for early detection, prognosis and therapy selection. This study aims to identify candidate biomarkers for FMC by comparing tissue proteomic profiles among grades of 31 FMC cats and six normal mammary tissues (control) using liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS). Candidate proteins identified by LC–MS/MS were validated by Western blotting and LC–MS/MS. Prognostic values of candidate proteins were evaluated using immunohistochemistry and survival analysis. Protein‐chemotherapy drug interaction networks were also evaluated. Among the 268 differential proteins observed, dermatopontin (DPT) expression was significantly downregulated, while sorting nexin 5 (SNX5) expression was elevated in cancerous tissues compared to controls ( p < 0.05). Immunohistochemistry results revealed a significant association of DPT and SNX5 with stages (DPT, p < 0.0001; SNX5, p = 0.046) and grades of FMC (DPT, p < 0.0001; SNX5, p = 0.04). Low DPT expression was associated with poor overall survival ( p = 0.02), along with Stage 4 FMC ( p = 0.0001), high mitotic count ( p = 0.003) and the presence of lymphovascular invasion ( p = 0.003). Moreover, protein‐chemotherapy drug interaction showed a relationship of DPT with doxorubicin, lapatinib and neratinib. This study identified DPT and SNX5 as potential diagnostic and therapeutic targets for FMC, with DPT emerging as a promising prognostic biomarker.
1 July 2026 in Journal of Veterinary Internal Medicine
Background: Chronic gingivostomatitis in cats is a debilitating inflammatory disease marked by severe oral pain and systemic immune dysregulation. Although localized oral pathology is well-documented, the systemic peptidomic profile remains largely unclear. Hypothesis/Objectives: Characterize the serum peptidomic profiles of cats with feline chronic gingivostomatitis (FCGS) and identify systemic biomarkers and signaling hubs that drive disease pathogenesis and therapeutic interactions. Animals: Client-owned cats with clinically and histopathologically confirmed FCGS (n = 34) and healthy controls (n = 18). Methods: A case–control, cross-sectional study was conducted. All cats were screened for feline leukemia virus, feline immunodeficiency virus, and feline heartworm infections. Serum samples were analyzed using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) to produce peptide mass fingerprints. Detailed peptide identification was conducted using nanoscale liquid chromatography–tandem mass spectrometry (nano LC–MS/MS). Functional enrichment and protein–protein/chemical interaction networks were developed using ShinyGO and the Kyoto Encyclopedia of Genes and Genomes database. Results: Both MALDI-TOF MS and nano LC–MS/MS identified distinct systemic protein signatures that distinguished FCGS from controls. Fifteen proteins showed significant changes, with 13 increased (including inflammatory markers such as interleukin (IL)-6 and interferon-γ) and 2 decreased (gastrin, IL-18). Network analysis identified 8 key proteins (eg, p21(CDKN1A), CASP1, IL-6) that interact with FCGS drug treatments. These systemic changes focus on the Janus kinase–signal transducers and activators of transcription (JAK–STAT) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT; PI3K–Akt) pathways, which are important therapeutic targets. Conclusions and clinical importance: Our study provides a molecular framework for FCGS. Whereas MALDI-TOF MS enables rapid systemic profiling, nano LC–MS/MS identifies key dysregulated pathways, specifically IL-6/JAK–STAT and PI3K–Akt. These findings offer potential therapeutic targets and a basis for monitoring molecular pathology in affected cats.
Feline mammary carcinomas (FMCs) are heterogeneous neoplasms often comprising multiple histological patterns within a single case. The current practice of focusing on a prominent subtype hinders prognostic accuracy and potentially produces suboptimal therapeutic decisions. This retrospective study proposed criteria for grouping these mixed patterns and evaluated their prognostic significance in FMCs. The criteria were based on the tubular carcinoma composition and adopted from those of human breast cancer. Eighty-seven cats with FMCs were divided into groups according to tubular carcinoma composition: pure tubular carcinoma (PTC, n = 34), tubular carcinoma mixed with other subtypes (TMC, n = 16), and nontubular carcinoma (NTC, n = 37). Prognostic factors and overall survival (OS) were compared among the groups. The PTC and TMC groups were significantly associated with early-stage FMCs ( P = .03) and low argyrophilic nucleolar organizer region values ( P = .02). Conversely, NTCs had the poorest prognosis ( P = .03) and were associated with incomplete surgical margins ( P = .004), advanced clinical stage ( P < .001), and high histological grade ( P < .001) on multivariable analysis. Median OS for the PTC, TMC, and NTC groups was 221, 242, and 147 days, respectively. Considering individual histological subtypes, cats with adenosquamous carcinoma had a shorter OS (60 days) than those with comedocarcinoma (147 days) and tubular carcinoma (240 days, P < .001). These criteria were associated with FMC outcome in this cohort, providing a potentially useful framework for prognosis. However, further validation through prospective studies is needed to fully establish their clinical utility.